Edition:
United States

Regeneron Pharmaceuticals Inc (REGN.OQ)

REGN.OQ on NASDAQ Stock Exchange Global Select Market

469.85USD
21 Aug 2017
Change (% chg)

$1.87 (+0.40%)
Prev Close
$467.98
Open
$467.75
Day's High
$472.29
Day's Low
$467.75
Volume
21,469
Avg. Vol
309,245
52-wk High
$543.50
52-wk Low
$325.62

REGN.OQ

Chart for REGN.OQ

About

Regeneron Pharmaceuticals, Inc. is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have... (more)

Overall

Beta: 1.66
Market Cap(Mil.): $50,145.10
Shares Outstanding(Mil.): 107.15
Dividend: --
Yield (%): --

Financials

  REGN.OQ Industry Sector
P/E (TTM): 46.98 78.89 32.56
EPS (TTM): 9.96 -- --
ROI: 18.73 2.83 14.89
ROE: 24.06 5.09 16.13

Regeneron to abandon drug for common respiratory virus

Aug 14 Regeneron Pharmaceuticals Inc said it would stop developing its drug to prevent respiratory syncytial virus (RSV) infections in infants, after it failed a late-stage study.

Aug 14 2017

BRIEF-Regeneron's drug for respiratory virus fails late-stage study

* Regeneron to discontinue development of suptavumab for respiratory syncytial virus

Aug 14 2017

BRIEF-Temasek Holdings takes stake in JPMorgan, Biogen, Celgene

* Temasek Holdings (Private) Ltd takes share stake in JPMorgan Chase & Co of 264,337 shares

Aug 14 2017

Regeneron beats profit view, to end antibody deal with Sanofi

Regeneron Pharmaceuticals Inc reported a much better-than-expected quarterly profit on strong demand for its flagship Eylea drug and said it would end one of its agreements with France's Sanofi SA to develop antibodies by the end of the year.

Aug 03 2017

UPDATE 4-Regeneron beats profit view, to end antibody deal with Sanofi

* Shares close down 2 pct on plans to scrap antibody deal (Adds details about Sanofi antibody deal, Sanofi and analyst comments, updates shares)

Aug 03 2017

US STOCKS-Wall St opens flat as tech stocks slip

* Indexes down: Dow 0.05 pct, S&P 0.14 pct, Nasdaq 0.06 pct (Updates to open)

Aug 03 2017

BRIEF-Regeneron says expects that Dupixent will have broad market access in the United States by the end of the year

* Regeneron CEO says U.S. Eylea sales have grown steadily since launch, without any price increases. Growth has been driven by new patients & new indications

Aug 03 2017

US STOCKS-Wall St set to open flat after Dow breaches 22,000

* Futures: Dow down 1 pt, S&P off 1 pt, Nasdaq up 7 pts (Adds details, comment, updates prices)

Aug 03 2017

BRIEF-Regeneron Q2 non-gaap earnings per share $4.17

* Regeneron reports second quarter 2017 financial and operating results

Aug 03 2017

Regeneron quarterly profit nearly doubles

Aug 3 Regeneron Pharmaceuticals Inc reported a nearly 98 percent rise in quarterly profit on Thursday, partly helped by higher demand for its flagship eye treatment, Eylea.

Aug 03 2017

Competitors

  Price Chg
Novartis AG (NOVN.S) CHF79.85 +0.05
Pfizer Inc. (PFE.N) $32.68 +0.01
Bayer AG (BAYGn.DE) €106.00 -1.90
Bayer AG (BAYE.F) -- --
Sanofi SA (SASY.PA) €81.76 -0.50
Merck & Co., Inc. (MRK.N) $61.69 +0.20
Amgen, Inc. (AMGN.OQ) $167.71 +0.42
Roche Holding Ltd. (ROG.S) CHF240.90 -0.50
Roche Holding Ltd. (RO.S) CHF244.50 0.00
Eli Lilly and Co (LLY.N) $77.26 +0.19

Earnings vs. Estimates